The World Health Organization (WHO) today recommended the use of anti-inflammatory monoclonal antibodies—tocilizumab and sarilumab—alongside corticosteroids for treating patients who have severe or critical COVID-19 infections.In other global developments, some countries including Indonesia, Vietnam, and Bangladesh, reported new record daily highs for infections, as COVID-19 cases continued to rise in parts of Europe.Meta-analysis reveals life-saving impactThe WHO's treatment recommendation comes in the wake of a study published today in the Journal of the American Medical Association (JAMA), in which researchers analyzed 27 randomized trials that involved nearly 11,000 patients.They found that the interleukin-6 antagonists tocilizumab and